TRAF2 and atherosclerosis: It is noteworthy to mention that a selective blocker of the interaction between CD40 and TRAF6 (“TRAF-STOPs”) that does not affect CD40-TRAF2/3/5 interactions and preserves CD40-mediated immunity reduces atherosclerosis, likely by impairing inflammatory leukocyte recruitment (39).